Evidence map›Paper›PMID 42158413›Full record

ArticleFrontiers in oncology2026

C5orf46: a promising prognosis risk indicator with implication in the remodeling of KIRC and pan-cancer tumor microenvironments.

Lei Miao, Fei Wang, Xuzhi Wang, Huijun Yang, Jiayao Li, Siying Liu, Ningning Shen, Zhiqing Yang, Lifang Gao, Wenxia Ma and 1 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lei MiaoBasical College of ShanXi Medical University, Taiyuan, Shanxi, China.
Fei WangSecond Clinical Medical College of ShanXi Medical University, Taiyuan, Shanxi, China.
Xuzhi WangSecond Clinical Medical College of ShanXi Medical University, Taiyuan, Shanxi, China.
Huijun YangSecond Clinical Medical College of ShanXi Medical University, Taiyuan, Shanxi, China.
Jiayao LiSecond Clinical Medical College of ShanXi Medical University, Taiyuan, Shanxi, China.
Siying LiuSecond Clinical Medical College of ShanXi Medical University, Taiyuan, Shanxi, China.
Ningning ShenDepartment of Pathology, Second Hospital of ShanXi Medical University, Taiyuan, Shanxi, China.
Zhiqing YangDepartment of Pathology, Second Hospital of ShanXi Medical University, Taiyuan, Shanxi, China.
Lifang GaoDepartment of Pathology, Second Hospital of ShanXi Medical University, Taiyuan, Shanxi, China.
Wenxia MaDepartment of Pathology, Second Hospital of ShanXi Medical University, Taiyuan, Shanxi, China.
Chen WangDepartment of Pathology, Second Hospital of ShanXi Medical University, Taiyuan, Shanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: C5orf46 is a recently discovered tumor-progression-related gene whose function in most cancers is still unknown, especially its potential role in regulating the tumor microenvironment (TME). The aim of the study is to explore the function of the C5orf46 gene in human pan-cancer, including kidney renal clear cell carcinoma (KIRC), for potential clinical application. Methods: The study started with the physicochemical properties of C5orf46, then the gene expression as well as alteration patterns in diverse cancers, followed by its post-transcription modulation, and then survival analysis. Moreover, the correlations between C5orf46 and multiple cancer TME-related parameters, including angiogenesis, extracellular matrix (ECM) degradation, and immune infiltration, were explored sequentially. Furthermore, C5orf46's association with other critical cancer features, for instance, cancer stemness, tumor epithelial-mesenchymal transition (EMT), and DNA repair, was also investigated. Results: Firstly, the physicochemical properties, including amino acid composition, estimated molecular weight, and protein half-life, of the C5orf46 gene were computed sequentially. Then, based on gene expression as well as survival analysis results, C5orf46 was shown to be upregulated in various human cancers, wherein KIRC showed the greatest difference in C5orf46 expression between cancer and corresponding normal tissues. The change in expression was partly due to DNA methylation modulation. Meanwhile, of greater clinical significance, the upregulated C5orf46 expression was correlated with both worse patients' overall survival and shorter recurrence-free survival. Moreover, the association between C5orf46 and multiple critical cancer traits, including microenvironment angiogenesis, immune infiltration, ECM degradation, and cancer EMT, was validated. Furthermore, the C5orf46 gene was indicated to correlate with the sensitivity of several chemotherapy-related drugs. Conclusions: Based on TCGA pan-cancer data and validation of local hospital samples, C5orf46 was indicated to potentially work as an oncogene in diverse cancers, and the gene was associated with multiple critical cancer traits.

Indexed as

C5orf46clear cell renal cell carcinomaimmune infiltrationprognosis risktumor microenvironment

Identifiers

PMID42158413
PMCPMC13180555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.